SCHEMBL8917088

SCHEMBL8917088

CC(O)c1ccc2c(c1)CCC(=O)N2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 7/20 0.53
KIF11 P52732 3/20 0.52
NPC1 O15118 2/20 0.47
MAPK13 O15264 1/20 0.47
MAPK12 P53778 1/20 0.47
MAPK11 Q15759 1/20 0.47
MAPK14 Q16539 1/20 0.47
TBXAS1 P24557 3/20 0.47
PDE3B Q13370 3/20 0.47
PDE3A Q14432 3/20 0.47
CRBN Q96SW2 1/20 0.46
GRIN2B Q13224 1/20 0.45
MAPT P10636 2/20 0.44
MMP12 P39900 1/20 0.44
RAB9A P51151 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9148322 0.89 KCNH2 (0.58) KCNH2KIF11NPC1MAPK13MAPK12
SCHEMBL2218608 0.87 CA9 (0.54) KCNH2KIF11NPC1MAPK13MAPK12
SCHEMBL2611074 0.87 KIF11 (0.66) KCNH2KIF11NPC1MAPK13MAPK12
SCHEMBL24192217 0.85 AHR (0.53) PDE3BPDE3AGRIN2BCYP1A2CYP11B1
SCHEMBL24191820 0.85 AHR (0.53) PDE3BPDE3AGRIN2BCYP1A2CYP11B1
SCHEMBL20801733 0.84 KIF11 (0.52) KCNH2KIF11NPC1MAPK13MAPK12
SCHEMBL22184244 0.84 KIF11 (0.52) KCNH2KIF11NPC1MAPK13MAPK12
SCHEMBL9485923 0.84 KIF11 (0.52) KCNH2KIF11NPC1MAPK13MAPK12
SCHEMBL10464330 0.83 KCNH2 (0.50) KCNH2KIF11NPC1MAPK13MAPK12
SCHEMBL11574095 0.83 KIF11 (0.52) KCNH2KIF11NPC1MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5612354-A CONTROLLING CELL GROWTH AND DIFFERENTIATION, RETINOIC ACID METABOLISM JANSSEN PHARMACEUTICA N.V. (BE) 1997-03-18 US disclosed
US-5441954-A Treatment of disorders characterized by increased proliferation and/or abnormal differentiation of cells JANSSEN PHARMACEUTICA N. V. (BE) 1995-08-15 US disclosed
CN-1106005-A A process for preparing (1H-azol-1-ylmethyl) substituted quinoxaline derivatives JANSSEN PHARMACEUTICA NV (BE) 1995-08-02 CN disclosed
CN-1106004-A A process for preparing (1H-azol-1-ylmethyl) substituted quinazoline derivatives JANSSEN PHARMACEUTICA NV (BE) 1995-08-02 CN disclosed
EP-0371564-B1 (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives JANSSEN PHARMACEUTICA NV (BE) 1995-07-12 EP disclosed
US-5268380-A Therapy for keratinization in mammals JANSSEN PHARMACEUTICA N.V. (BE) 1993-12-07 US disclosed
US-5185346-A Antiandrogenic agents; suppress elimination of retinoids; anticarcinogenic agents HANSSEN PHARMACEUTICA (BE) 1993-02-09 US disclosed
CN-1042912-A (1H-oxazol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives JANSSEN PHARMACEUTICA NV (BE) 1990-06-13 CN disclosed
EP-0371564-A2 (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1990-06-06 EP disclosed
US-4921862-A Carbostyril derivatives as combined thromboxane synthetase and cyclic-amp phosphodiesterase inhibitors SYNTEX (U.S.A.) INC. (US) 1990-05-01 US disclosed
US-4792561-A ANTICOAGULANTS, CARDIOVASCULAR DISORDERS SYNTEX (U.S.A.) INC. (US) 1988-12-20 US disclosed